ImmunoGen
NASDAQ: IMGN
$3.55
-$0.15 (-4.1%)
Closing price March 30, 2020
ImmunoGen shares jumped on Tuesday after the FDA advised that a new single-arm study in platinum-resistant ovarian cancer could support accelerated approval.
3 months ago
Last Updated: 2 months ago
ImmunoGen shares dropped on Monday after the firm released data from its late-stage ovarian cancer study at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.
6 months ago
Last Updated: 2 months ago
The top analyst upgrades, downgrades and initiations seen on Tuesday included Boeing, Booking, Camping World, Domino's Pizza, iRobot, MetLife, Neogen, Southern Copper, Vertex Pharmaceuticals and...
1 year ago
Last Updated: 1 month ago
The top analyst upgrades, downgrades and initiations seen on Monday included Alector, Bed Bath & Beyond, Dillard's, Foot Locker, Hasbro, Kraft Heinz, Vale, Xilinx and Zoetis.
1 year ago
Last Updated: 1 month ago
ImmunoGen shares were halved on Friday after the firm reported late-stage results from its ovarian cancer study.
1 year ago
Last Updated: 1 month ago
Here are five biotech stocks that are rated Buy by the Jefferies analysts, are trading under the $10 level and could provide investors with some solid upside potential.
1 year ago
Last Updated: 2 months ago
ImmunoGen shares benefited after the company presented data for its latest assessment of mirvetuximab soravtansine at the Society of Gynecologic Oncology annual meeting.
2 years ago
Last Updated: 2 months ago
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates for the rest of March.
2 years ago
Last Updated: 2 months ago
24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of March.
2 years ago
Last Updated: 2 months ago
The top analyst upgrades, downgrades and other research calls from Wednesday include AK Steel, Apple, Biogen, Electronic Arts, FitBit, Foot Locker, McDonald's and Pfizer.
2 years ago
Last Updated: 2 months ago
Cancer drug developer ImmunoGen posted sharply lower profits and revenues than analysts were expecting. The stock is taking a beating as a result.
2 years ago
Last Updated: 2 months ago
ImmunoGen saw its shares make a sharp turn downward on Thursday morning after the stock has seen an incredible year of trading so far.
2 years ago
Last Updated: 2 months ago
ImmunoGen announced this week that it has decided to partner with Jazz Pharmaceuticals, and investors have pushed Immunogen shares to a new 52-week high.
2 years ago
Last Updated: 2 months ago
ImmunoGen has decided to partner with Jazz Pharmaceuticals for the development and commercialization of two early-stage, hematology-related antibody-drug conjugate programs.
2 years ago
Last Updated: 2 months ago
The top analyst upgrades, downgrades and other research calls from Thursday include AutoZone, O'Reilly Automotive, Immunogen, Medtronic, Nike, OncoSec Medical and Schlumberger.
2 years ago
Last Updated: 2 months ago